Gamida Cell Ltd.

208 articles about Gamida Cell Ltd.

• Gamida Cell to Participate in Upcoming Investor Conferences

  9/8/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that company management will participate in three upcoming virtual investor conferences in September: H.C. Wainwright 22 nd Annual Global Investment Conference Date: Monday, September 14, 2020 Presentation: 11:00 a.m. ET Cantor Virtual Global Healthcare Confer

• Gamida Cell Announces Two-Part Virtual Miniseries Focused on Omidubicel to Take Place in September

  9/3/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will host a two-part virtual miniseries in September focused on key topics related to omidubicel , an advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of a bone marrow transplant. The webcasts will take

• Gamida Cell to Provide Webcast of Its Annual Meeting of Stockholders

  8/17/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will webcast its Annual Meeting of Stockholders on Thursday, September 10, 2020, at 10:00 a.m. ET (5:00 p.m. Israel time) at 12 Leshem Street, Kiryat Gat, 8258412, Israel. During the meeting, Julian Adams, Ph.D., Gamida Cell’s chief executive officer, will present an overview o

• Gamida Cell Announces the Date of Its Second Quarter 2020 Financial Results and Webcast

  8/4/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, August 11, 2020, at 8:30 a.m. ET to review its second quarter 2020 financial results and provide an update on the company. The webcast will be available on the “Investors & Media” section of the Gam

• Gamida Cell Announces Appointment of Michele Korfin as Chief Operating and Chief Commercial Officer

  7/21/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the appointment of Michele Korfin as chief operating and chief commercial officer. Ms. Korfin brings over 20 years of experience in oncology, focused on business operations and commercialization of novel therapies. In this role, she will have oversight of manufacturing and comm

• Gamida Cell Announces Appointment of David Fox to Its Board of Directors

  7/7/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that David Fox has been appointed to Gamida Cell’s board of directors as an independent member. Mr. Fox brings significant leadership, company-building and business development experience to Gamida Cell’s board of directors as the company advances its clinical development candid

• Gamida Cell to Present at the JMP Securities Virtual Hematology and Oncology Forum

  6/12/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will participate in a fireside chat at the JMP Securities Virtual Hematology and Oncology Forum on Thursday, June 18, 2020 at 2:00 p.m. ET. A live webcast of the presentation will be available on the Investors sectio

• Gamida Cell Reports First Quarter 2020 Financial Results and Provides Company Update

  5/21/2020

  Primary endpoint achieved in global, randomized, Phase 3 study of omidubicel; Initiation of BLA submission planned for fourth quarter of 2020 — – Additional data from GDA-201 program expected in second half of 2020 – – $60 million follow-on offering expected to close today – – Company to host conference call at 8:30 a.m. ET today – BOSTON--( BUSINESS WIRE )-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company com

• Gamida Cell Announces Pricing of $60 Million Public Offering of Ordinary Shares - May 19, 2020

  5/19/2020

  Gamida Cell Ltd. announced the pricing of an underwritten public offering of 13,333,334 ordinary shares at a public offering price of $4.50 per share for aggregate gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and estimated offering expenses.

• Gamida Cell Announces the Date of Its First Quarter 2020 Financial Results and Webcast

  5/18/2020

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Thursday, May 21, 2020, at 8:30 a.m. ET to review its first quarter 2020 financial results and provide an update on the company. The webcast will be available on the “Investors” section of the Gamida Cell websit

• Gamida Cell Announces Launch of Proposed Public Offering of Ordinary Shares - May 18, 2020

  5/18/2020

  Gamida Cell Ltd., an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, announced the launch of a proposed follow-on public offering of its ordinary shares.

• Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies

  5/12/2020

  Gamida Cell Ltd. announced positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy in development as a potential life-saving treatment option for patients in need of bone marrow transplant.

• Gamida Cell Announces Updated Data from Phase 1 Study of GDA-201 to be Presented at the Annual Meeting of the European Society for Blood and Marrow Transplantation

  3/2/2020

  Gamida Cell Ltd. (Nasdaq: GMDA),will be presented during an oral session at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), which is being held March 22 through March 25, 2020, in Madrid, Spain.

• Gamida Cell Announces the Date of Its Full Year 2019 Financial Results and Webcast

  2/19/2020

  Gamida Cell Ltd. announced that the company will host a conference call and live audio webcast on Tuesday, February 25, 2020, at 8:30 a.m. ET to review its full year 2019 financial results and provide an update on the company.

• Gamida Cell Announces 2020 Goals and Provides Company Update

  1/13/2020

  Gamida Cell Ltd. reported its expected milestones for 2020-2021, which highlight the company’s progress advancing its clinical development candidates

• Gamida Cell Announces Results from Phase 1 Study of GDA-201 and New Mechanism of Action Data at ASH 2019 Annual Meeting

  12/9/2019

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced updated results from a Phase 1 clinical study of GDA-201, an investigational, natural killer (NK) cell-based cancer immunotherapy for the treatment of patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), at the 61st Annual Meeting of the American Society of Hematology (ASH)

• Gamida Cell to Present at the 31st Annual Piper Jaffray Healthcare Conference

  11/21/2019

  Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph.D., the company’s chief executive officer, will participate in a “fireside chat” at the 31st Annual Piper Jaffray Healthcare Conference on Thursday, December 5, 2019, at 1:00 p.m. ET in New York City.

• Gamida Cell Reports Third Quarter 2019 Financial Results and Provides Company Update

  11/13/2019

  Additional results from Phase 1 study of GDA-201 and new data on NAM technology platform to be presented at 61st Annual Meeting of the American Society of Hematology

• Gamida Cell Reports Second Quarter 2019 Financial Results and Provides Company Update

  8/6/2019

  Gamida Cell Ltd., a leading cellular and immune therapeutics company, reported financial results for the quarter ended June 30, 2019.

• Gamida Cell Announces the Date of Its Second Quarter 2019 Financial Results and Webcast

  7/23/2019

  Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that the company will host a conference call and live audio webcast on Tuesday, August 6, 2019, at 8:30 a.m. ET to review its second quarter 2019 financial results and provide an update on the company.